- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
HD-ASCT Demonstrates Improved PFS Vs Non-Myeloablative Chemoimmunotherapy in Primary CNS Lymphoma
December 13th 2022, 8:52pm
ASH Annual Meeting and Exposition
Consolidation therapy with high-dose chemotherapy and autologous stem cell transplantation improved progression-free survival vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.
BCMA/CD19 Dual-targeting CAR T-cell Therapy Shows 100% MRD Negativity Rate in Newly Diagnosed Multiple Myeloma
December 13th 2022, 8:47pm
ASH Annual Meeting and Exposition
Among patients with newly diagnosed high-risk multiple myeloma, treatment with BCMA/CD19 dual-targeting FasTCAR-T Cells resulted in an overall response rate of 100%, with all treated patients evaluable for minimal residual disease showing minimal residual disease negativity to 12 months.
Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual Anemia
December 13th 2022, 8:04pm
ASH Annual Meeting and Exposition
Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.
GVHD Prophylactic Regimen Improves 1-Year GRFS Vs Standard in Patients With Hematologic Malignancies Post-HCT
December 13th 2022, 6:40pm
ASH Annual Meeting and Exposition
Administration of cyclophosphamide, tacrolimus, and mycophenolate mofetil improved 1-year GVHD relapse-free survival compared with tacrolimus plus methotrexate in patients with hematologic malignancies undergoing reduced intensity conditioning allogeneic hematopoietic cell transplantation.
Cilta-Cel Shows Efficacy and Tolerability in Multiple Myeloma, Potentially Filling Unmet Need in Early-Line Therapy
December 13th 2022, 6:20pm
ASH Annual Meeting and Exposition
The CAR-T cell therapy ciltacabtagene autoleucel has expanded options for adult patients with relapsed/refractory multiple myeloma after 4 or more lines of prior therapy in the United States, and has continued to display promising efficacy in patients with multiple myeloma following early relapse.
Olverembatinib Elicits Efficacy in US Patients With Ponatinib-Resistant, T315I-Mutant CML, and Ph-Positive ALL
December 13th 2022, 5:35pm
ASH Annual Meeting and Exposition
Olverembatinib elicited encouraging responses and tolerability in US patients with ponatinib-resistant chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and in patients with CML whose tumors have a T315I mutation.
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
December 13th 2022, 3:00pm
ASH Annual Meeting and Exposition
Treatment with zanubrutinib (Brukinsa) reduced the risk of progression or death by 35% compared with ibrutinib (Imbruvica) for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Blinatumomab/Consolidation Chemo Combo Improves OS in MRD-Negative B-cell ALL
December 13th 2022, 3:00pm
ASH Annual Meeting and Exposition
Blinatumomab followed by consolidation chemotherapy led to a 58% reduction in the risk of death compared with standard consolidation chemotherapy alone in adult patients with newly diagnosed minimal residual disease–negative B-cell acute lymphoblastic leukemia.
VITAL Post-Hoc Analysis Shows Birtamimab Significantly Improves Time to All-Cause Mortality in Stage IV AL Amyloidosis
December 13th 2022, 2:50pm
ASH Annual Meeting and Exposition
Birtamimab demonstrated a significant survival benefit in patients with Mayo Stage IV amyloid light chain amyloidosis at month 9.
Dr Topp on the Efficacy of Glofitamab Plus R-CHOP in Previously Untreated DLBCL
December 12th 2022, 11:36pm
Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.
Ibrutinib Improves Time to Next Therapy Vs Acalabrutinib in Real-world Analysis of Patients With CLL
December 12th 2022, 10:09pm
ASH Annual Meeting and Exposition
The use of frontline ibrutinib was associated with a longer time to next treatment compared with acalabrutinib in patients with chronic lymphocytic leukemia.
Amid Withdrawal News, Final DREAMM-2 Analysis Confirms Durability of Belantamab Mafotodin Monotherapy in Relapsed/Refractory Multiple Myeloma
December 12th 2022, 9:25pm
ASH Annual Meeting and Exposition
Single-agent belantamab mafodotin continued to produce rapid, deep, and durable responses in patients with relapsed/refractory multiple myeloma.
Zanubrutinib Demonstrates Efficacy and Safety in Acalabrutinib-Intolerant Patients with B-Cell Malignancies
December 12th 2022, 9:24pm
ASH Annual Meeting and Exposition
Updated results from the ongoing phase 2 BGB-3111-215 trial showed that zanubrutinib provided clinically meaningful benefit to a large majority of efficacy-evaluable patients with B-cell malignancies who were intolerant to acalabrutinib.
Momelotinib Responses Upheld Through 48 Weeks in Patients With Anemic Myelofibrosis
December 12th 2022, 9:07pm
ASH Annual Meeting and Exposition
Momelotinib elicited durable symptom, transfusion independence, and splenic responses through 48 weeks of treatment in patients with myelofibrosis who have anemia and previously received a JAK inhibitor.
Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Prolongs PFS, Compared With Historical Control in Relapsed/Refractory Multiple Myeloma
December 12th 2022, 8:55pm
ASH Annual Meeting and Exposition
The combination of belantamab mafodotin, pomalidomide, and dexamethasone elicited encouraging responses and survival benefits in patients with triple class–exposed or refractory multiple myeloma.
Unpacking Data in Multiple Myeloma, Non-Hodgkin Lymphoma, and GVHD: Drs Noopur Raje, Joshua Brody, and Ryotaro Nakamura
December 12th 2022, 8:32pm
OncLive News Network: On Location at ASH 2022
In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.
Mosunetuzumab Elicits Long-Term Responses in Relapsed/Refractory Follicular Lymphoma
December 12th 2022, 8:32pm
ASH Annual Meeting and Exposition
Mosunetuzumab demonstrated durable responses and a low rate of adverse events linked with treatment discontinuation in patients with relapsed/refractory follicular lymphoma, according to an updated analysis of the pivotal phase 2 GO29781 study.
Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCL
December 12th 2022, 7:23pm
ASH Annual Meeting and Exposition
Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.
Low-Dose Lenalidomide Reduces Risk of Transfusion Dependency, Provides Clonal Response and Safety Benefits in MDS
December 12th 2022, 6:55pm
ASH Annual Meeting and Exposition
Low doses of lenalidomide prolonged time to and decreased the risk of transfusion dependency and induced quality clonal responses with no increases in progression rate or clonal evolution in patients with low-risk myelodysplastic syndrome.